MorphoSys AG (MOR)

Market Cap	999.13M
Revenue (ttm)	n/a
Net Income (ttm)	n/a
Shares Out	136.68M
EPS (ttm)	0.68
PE Ratio	10.91
Forward PE	322.58
Dividend	n/a
Ex-Dividend Date	n/a

Volume	40,236
Open	7.46
Previous Close	7.26
Day's Range	7.20 - 7.46
52-Week Range	3.17 - 8.67
Beta	0.72
Analysts	Buy
Price Target	12.81 (+75.24%)
Earnings Date	Nov 15, 2023

About MOR

MorphoSys AG, a commercial-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutic antibodies for patients suffering from cancer and autoimmune diseases in the United States. It offers Tafasitamab, an antibody for the treatment of B cell malignancies, including diffuse large B-cell lymphoma, follicular lymphoma, and marginal zone lymphoma. The company also develops Pelabresib, a small molecule to treat myelofibrosis; Felzartamab, an antibody directed against CD38 for the treatment of anti-PLA...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Mar 9, 1999
• Employees: 544
• Stock Exchange: NASDAQ
• Ticker Symbol: MOR

Financial Performance

In 2022, MorphoSys AG's revenue was $278.27 million, an increase of 54.93% compared to the previous year's $179.61 million. Losses were -$151.06 million, -70.64% less than in 2021.

Analyst Forecast

According to 4 analysts, the average rating for MOR stock is "Buy." The 12-month stock price forecast is $12.81, which is an increase of 75.24% from the latest price.

Price Target

$12.81

(75.24% upside)

Analyst Consensus: Buy